Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant
Authors
Keywords
-
Journal
LEUKEMIA
Volume 31, Issue 1, Pages 177-185
Publisher
Springer Nature
Online
2016-06-10
DOI
10.1038/leu.2016.153
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Postibrutinib outcomes in patients with mantle cell lymphoma
- (2016) P. Martin et al. BLOOD
- Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment
- (2016) Andrew Stiff et al. CANCER RESEARCH
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypermorphic mutation of phospholipase C, 2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
- (2015) T.-M. Liu et al. BLOOD
- Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma
- (2015) Shuang Q. Zhang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Characterization of All Possible Single-Nucleotide Change Caused Amino Acid Substitutions in the Kinase Domain of Bruton Tyrosine Kinase
- (2015) Jouni Väliaho et al. HUMAN MUTATION
- Non-coding recurrent mutations in chronic lymphocytic leukaemia
- (2015) Xose S. Puente et al. NATURE
- Mutations driving CLL and their evolution in progression and relapse
- (2015) Dan A. Landau et al. NATURE
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targets for Ibrutinib Beyond B Cell Malignancies
- (2015) A. Berglöf et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
- (2015) Kami J. Maddocks et al. JAMA Oncology
- PON-P2: Prediction Method for Fast and Reliable Identification of Harmful Variants
- (2015) Abhishek Niroula et al. PLoS One
- Ibrutinib inhibits BCR and NF- B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
- (2014) S. E. M. Herman et al. BLOOD
- Ibrutinib treatment ameliorates murine chronic graft-versus-host disease
- (2014) Jason A. Dubovsky et al. JOURNAL OF CLINICAL INVESTIGATION
- Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies
- (2014) Sabine Ponader et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional characterization of BTK C481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors
- (2014) S Cheng et al. LEUKEMIA
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
- (2014) D. Chiron et al. Cancer Discovery
- Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
- (2013) B. Y. Chang et al. BLOOD
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Agammaglobulinemia: causative mutations and their implications for novel therapies
- (2013) Anna Berglöf et al. Expert Review of Clinical Immunology
- Ibrutinib and novel BTK inhibitors in clinical development
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
- (2013) Jan A. Burger et al. LEUKEMIA & LYMPHOMA
- Dual Phosphorylation of Btk by Akt/Protein Kinase B Provides Docking for 14-3-3ζ, Regulates Shuttling, and Attenuates both Tonic and Induced Signaling in B Cells
- (2013) Dara K. Mohammad et al. MOLECULAR AND CELLULAR BIOLOGY
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibitors of BTK and ITK: State of the New Drugs for Cancer, Autoimmunity and Inflammatory Diseases
- (2013) L. Vargas et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials
- (2013) Jan A. Burger Current Hematologic Malignancy Reports
- Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
- (2012) Joseph J. Buggy et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulation of Nucleocytoplasmic Shuttling of Bruton's Tyrosine Kinase (Btk) through a Novel SH3-Dependent Interaction with Ankyrin Repeat Domain 54 (ANKRD54)
- (2012) M. O. Gustafsson et al. MOLECULAR AND CELLULAR BIOLOGY
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
- (2011) Lili Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rate, molecular spectrum, and consequences of human mutation
- (2010) M. Lynch PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Primary B Cell Immunodeficiencies: Comparisons and Contrasts
- (2009) Mary Ellen Conley et al. Annual Review of Immunology
- Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
- (2009) Abdalla J. Mohamed et al. IMMUNOLOGICAL REVIEWS
- Expression profiling of chicken DT40 lymphoma cells indicates clonal selection of knockout and gene reconstituted cells
- (2008) Hossain M. Nawaz et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation